{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T20:59:23Z","timestamp":1783717163232,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T00:00:00Z","timestamp":1537401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00774-018-0957-5","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T17:38:27Z","timestamp":1537465107000},"page":"685-693","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Congenital hypophosphataemia in adults: determinants of bone turnover markers and amelioration of renal phosphate wasting following total parathyroidectomy"],"prefix":"10.1007","volume":"37","author":[{"given":"Malachi J.","family":"McKenna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Martin-Grace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Twomey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Kilbane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,20]]},"reference":[{"key":"957_CR1","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1210\/jc.2011-1319","volume":"97","author":"EA Imel","year":"2012","unstructured":"Imel EA, Econs MJ (2012) Approach to the hypophosphatemic patient. J Clin Endocrinol Metab 97:696\u2013706","journal-title":"J Clin Endocrinol Metab"},{"key":"957_CR2","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrendo.2011.218","volume":"8","author":"LD Quarles","year":"2012","unstructured":"Quarles LD (2012) Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol 8:276\u2013286","journal-title":"Nat Rev Endocrinol"},{"key":"957_CR3","doi-asserted-by":"publisher","first-page":"F282","DOI":"10.1152\/ajprenal.90742.2008","volume":"297","author":"J Gattineni","year":"2009","unstructured":"Gattineni J, Bates C, Twombley K, Dwarakanath V, Robinson ML, Goetz R, Mohammadi M, Baum M (2009) FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Ren Physiol 297:F282\u2013F291","journal-title":"Am J Physiol Ren Physiol"},{"key":"957_CR4","first-page":"23","volume":"37","author":"OL Bijvoet","year":"1969","unstructured":"Bijvoet OL (1969) Relation of plasma phosphate concentration to renal tubular reabsorption of phosphate. Clin Sci 37:23\u201336","journal-title":"Clin Sci"},{"key":"957_CR5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/000456329803500203","volume":"35","author":"RB Payne","year":"1998","unstructured":"Payne RB (1998) Renal tubular reabsorption of phosphate (TmP\/GFR): indications and interpretation. Ann Clin Biochem 35:201\u2013206","journal-title":"Ann Clin Biochem"},{"key":"957_CR6","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL (2011) A clinician\u2019s guide to X-linked hypophosphatemia. J Bone Miner Res 26:1381\u20131388","journal-title":"J Bone Miner Res"},{"key":"957_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00223-017-0363-3","volume":"102","author":"VV Shanbhogue","year":"2018","unstructured":"Shanbhogue VV, Hansen S, J\u00f8rgensen NR, Beck-Nielsen SS (2018) Impact of conventional medical therapy on bone mineral density and bone turnover in adult patients with X-linked hypophosphatemia: a 6-year prospective cohort study. Calcif Tissue Int 102:321\u2013328","journal-title":"Calcif Tissue Int"},{"key":"957_CR8","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/EC-13-0103","volume":"3","author":"A Linglart","year":"2014","unstructured":"Linglart A, Biosse-Duplan M, Briot K et al (2014) Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect 3:R13\u2013R30","journal-title":"Endocr Connect"},{"key":"957_CR9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/jcph.570","volume":"56","author":"X Zhang","year":"2016","unstructured":"Zhang X, Imel EA, Ruppe MD et al (2016) Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia. J Clin Pharmacol 56:176\u2013185","journal-title":"J Clin Pharmacol"},{"key":"957_CR10","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.3544","volume":"33","author":"M Collins","year":"2018","unstructured":"Collins M (2018) Burosumab: at long last, an effective treatment for FGF23-associated hypophosphatemia. J Bone Miner Res 33:1381\u20131382. \n                    https:\/\/doi.org\/10.1002\/jbmr.3544","journal-title":"J Bone Miner Res"},{"key":"957_CR11","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter TO, Whyte MP, Imel EA et al (2018) Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med 378:1987\u20131998","journal-title":"N Engl J Med"},{"key":"957_CR12","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1172\/JCI72829","volume":"124","author":"TO Carpenter","year":"2014","unstructured":"Carpenter TO, Imel EA, Ruppe MD et al (2014) Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Investig 124:1587\u20131597","journal-title":"J Clin Investig"},{"key":"957_CR13","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1210\/jc.2015-1551","volume":"100","author":"EA Imel","year":"2015","unstructured":"Imel EA, Zhang X, Ruppe MD et al (2015) Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. J Clin Endocrinol Metab 100:2565\u20132573","journal-title":"J Clin Endocrinol Metab"},{"key":"957_CR14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.bonr.2016.05.004","volume":"5","author":"MD Ruppe","year":"2016","unstructured":"Ruppe MD, Zhang X, Imel EA et al (2016) Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. Bone Rep 5:158\u2013162","journal-title":"Bone Rep"},{"key":"957_CR15","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna KL, Briot K, Imel EA et al (2018) A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res 33:1383\u20131393. \n                    https:\/\/doi.org\/10.1002\/jbmr.3475","journal-title":"J Bone Miner Res"},{"key":"957_CR16","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s00774-004-0594-z","volume":"23","author":"I Ros","year":"2005","unstructured":"Ros I, Alvarez L, Guanabens N, Peris P, Monegal A, Vazquez I, Cerda D, Ballesta AM, Munoz-Gomez J (2005) Hypophosphatemic osteomalacia: a report of five cases and evaluation of bone markers. J Bone Miner Metab 23:266\u2013269","journal-title":"J Bone Miner Metab"},{"key":"957_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1752-1947-8-84","volume":"8","author":"RK Crowley","year":"2014","unstructured":"Crowley RK, Kilbane M, King TF, Morrin M, O\u2019Keane M, McKenna MJ (2014) Hungry bone syndrome and normalisation of renal phosphorus threshold after total parathyroidectomy for tertiary hyperparathyroidism in X-linked hypophosphataemia: a case report. J Med Case Rep 8:84","journal-title":"J Med Case Rep"},{"key":"957_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(75)92736-1","volume":"2","author":"RJ Walton","year":"1975","unstructured":"Walton RJ, Bijvoet OL (1975) Nomogram for derivation of renal threshold phosphate concentration. Lancet 2:309\u2013310","journal-title":"Lancet"},{"key":"957_CR19","volume-title":"Defining, establishing and verifying reference intervals in the clinical laboratory","author":"GL Horowitz","year":"2010","unstructured":"Horowitz GL, Altaie S, Boyd JC (2010) Defining, establishing and verifying reference intervals in the clinical laboratory. Clinical Laboratory Standards Institute, Wayne"},{"key":"957_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1210\/jc.2010-2704","volume":"96","author":"AC Ross","year":"2011","unstructured":"Ross AC, Manson JE, Abrams SA et al (2011) The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96:53\u201358","journal-title":"J Clin Endocrinol Metab"},{"key":"957_CR21","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1210\/jcem.86.8.7761","volume":"86","author":"IA Holm","year":"2001","unstructured":"Holm IA, Nelson AE, Robinson BG, Mason RS, Marsh DJ, Cowell CT, Carpenter TO (2001) Mutational analysis and genotype\u2013phenotype correlation of the PHEX gene in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 86:3889\u20133899","journal-title":"J Clin Endocrinol Metab"},{"key":"957_CR22","unstructured":"Fadem SZ, Rosenthal B (2014) GFR calculators: serum creatinine and cystatin C (2012). \n                    http:\/\/mdrd.com\/\n                    \n                   Accessed 03 Mar 2014"},{"key":"957_CR23","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s00198-008-0660-9","volume":"19","author":"P Szulc","year":"2008","unstructured":"Szulc P, Delmas PD (2008) Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int 19:1683\u20131704","journal-title":"Osteoporos Int"},{"key":"957_CR24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/B978-012068700-8\/50012-8","volume-title":"Metabolic bone disease and clinically related disorders","author":"AM Parfitt","year":"1998","unstructured":"Parfitt AM (1998) Osteomalacia and related disorders. In: Avioli LV, Krane SM (eds) Metabolic bone disease and clinically related disorders, 3rd edn. Academic Press, Boston, pp 327\u2013386","edition":"3"},{"key":"957_CR25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1210\/jcem-52-3-463","volume":"52","author":"T Costa","year":"1981","unstructured":"Costa T, Marie PJ, Scriver CR, Cole DE, Reade TM, Nogrady B, Glorieux FH, Delvin EE (1981) X-linked hypophosphatemia: effect of calcitriol on renal handling of phosphate, serum phosphate, and bone mineralization. J Clin Endocrinol Metab 52:463\u2013472","journal-title":"J Clin Endocrinol Metab"},{"key":"957_CR26","first-page":"879","volume":"75","author":"W Sullivan","year":"1992","unstructured":"Sullivan W, Carpenter T, Glorieux F, Travers R, Insogna K (1992) A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 75:879\u2013885","journal-title":"J Clin Endocrinol Metab"},{"key":"957_CR27","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/jbmr.2310","volume":"30","author":"VV Shanbhogue","year":"2015","unstructured":"Shanbhogue VV, Hansen S, Folkestad L, Brixen K, Beck-Nielsen SS (2015) Bone geometry, volumetric density, microarchitecture, and estimated bone strength assessed by HR-pQCT in adult patients with hypophosphatemic rickets. J Bone Miner Res 30:176\u2013183","journal-title":"J Bone Miner Res"},{"key":"957_CR28","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1681\/ASN.2005010052","volume":"16","author":"O Gutierrez","year":"2005","unstructured":"Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16:2205\u20132215","journal-title":"J Am Soc Nephrol"},{"key":"957_CR29","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1210\/jc.2013-2705","volume":"98","author":"SK Bhadada","year":"2013","unstructured":"Bhadada SK, Palnitkar S, Qiu S, Parikh N, Talpos GB, Rao SD (2013) Deliberate total parathyroidectomy: a potentially novel therapy for tumor-induced hypophosphatemic osteomalacia. J Clin Endocrinol Metab 98:4273\u20134278","journal-title":"J Clin Endocrinol Metab"},{"key":"957_CR30","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1056\/NEJM196910022811404","volume":"281","author":"BL Riggs","year":"1969","unstructured":"Riggs BL, Sprague RG, Jowsey J, Maher FT (1969) Adult-onset vitamin-D-resistant hypophosphatemic osteomalacia. Effect of total parathyroidectomy. N Engl J Med 281:762\u2013766","journal-title":"N Engl J Med"},{"key":"957_CR31","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429\u2013435","journal-title":"J Bone Miner Res"},{"key":"957_CR32","doi-asserted-by":"publisher","first-page":"E79","DOI":"10.1152\/ajpendo.90539.2008","volume":"296","author":"X Bai","year":"2009","unstructured":"Bai X, Dinghong Q, Miao D, Goltzman D, Karaplis AC (2009) Klotho ablation converts the biochemical and skeletal alterations in FGF23 (R176Q) transgenic mice to a Klotho-deficient phenotype. Am J Physiol Endocrinol Metab 296:E79\u2013E88","journal-title":"Am J Physiol Endocrinol Metab"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-018-0957-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-018-0957-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-018-0957-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T23:18:42Z","timestamp":1568935122000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-018-0957-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,20]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["957"],"URL":"https:\/\/doi.org\/10.1007\/s00774-018-0957-5","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,20]]},"assertion":[{"value":"17 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Research support from Ultragenyx Pharmaceutical: MMcK, RC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}